What is the value of the acquisition?

Danaher has not disclosed the financial terms of the deal.

When is the deal expected to close?

The expected closing date has not been announced.

How will this acquisition affect DHR stock?

The stock showed no significant movement immediately; the deal is seen as positive for the diagnostics segment long-term.

Danaher Expands Diagnostics With StatLab Medical Products Deal

Danaher (DHR) announced that its Leica Biosystems unit has agreed to acquire StatLab Medical Products. The deal expands Danaher's diagnostics and anatomical pathology offerings with added consumables and instruments. Financial terms were not disclosed.

July 17, 2026

2 min read

Source: Simply Wall St.

Danaher Corporation (NYSE:DHR) announced that its subsidiary Leica Biosystems has entered a definitive agreement to acquire StatLab Medical Products. The acquisition aims to expand Danaher's diagnostics and anatomical pathology portfolio, adding consumables and instruments. Financial terms were not disclosed.

Deal Details

Acquirer: Leica Biosystems (Danaher subsidiary)
Target: StatLab Medical Products
Value: Not disclosed
Payment: Not disclosed
Premium: Not disclosed
Expected Close: Not disclosed

Rationale

The acquisition aligns with Danaher's strategy to strengthen its diagnostics segment, particularly in anatomical pathology. StatLab's consumables and instruments complement Leica Biosystems' existing offerings.

Regulatory Challenges

The deal is subject to regulatory approvals. Danaher has not indicated any expected hurdles.

Stock Impact

DHR stock showed no significant movement following the announcement. The deal is viewed as positive long-term for diagnostics, but the lack of financial details limits immediate market reaction.

Frequently Asked Questions

StatLab Medical Products is a company specializing in consumables and instruments for anatomical pathology and diagnostics.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.